Search Results - "May, Caitlin D"

Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression by May, Caitlin D, Sphyris, Nathalie, Evans, Kurt W, Werden, Steven J, Guo, Wenjun, Mani, Sendurai A

“…Aberrant activation of a latent embryonic program - known as the epithelial-mesenchymal transition (EMT) - can endow cancer cells with the migratory and…”
Get full text

Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma by Roland, Christina L, Boland, Genevieve M, Demicco, Elizabeth G, Lusby, Kristelle, Ingram, Davis, May, Caitlin D, Kivlin, Christine M, Watson, Kelsey, Al Sannaa, Ghadah A, Wang, Wei-Lien, Ravi, Vinod, Pollock, Raphael E, Lev, Dina, Cormier, Janice N, Hunt, Kelly K, Feig, Barry W, Lazar, Alexander J, Torres, Keila E

“…Vascular leiomyosarcomas are a rare subtype of leiomyosarcomas that most commonly affect the inferior vena cava and account for 5% of all leiomyosarcomas…”
Get more information

Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma by Roland, Christina L., May, Caitlin D., Watson, Kelsey L., Al Sannaa, Ghadah A., Dineen, Sean P., Feig, Rachel, Landers, Sharon, Ingram, Davis R., Wang, Wei-Lien, Guadagnolo, B. Ashleigh, Feig, Barry, Hunt, Kelly K., Cormier, Janice N., Lazar, Alexander J., Torres, Keila E.

“…Background Undifferentiated pleomorphic sarcomas (UPS) present a diagnostic and therapeutic challenge. Identification of prognostic molecular markers is…”
Get full text

The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma by Bill, Kate Lynn J, Garnett, Jeannine, Ma, Xiaoyan, May, Caitlin D, Bolshakov, Svetlana, Lazar, Alexander J, Lev, Dina C, Pollock, Raphael E

“…Dedifferentiated liposarcomas (DDLPS) are highly resistant to conventional chemo- and radiotherapies, with surgical resection remaining the classic treatment…”
Get full text

Long-Term Outcomes in Patients with Radiation-Associated Angiosarcomas of the Breast Following Surgery and Radiotherapy for Breast Cancer by Torres, Keila E., Ravi, Vinod, Kin, Katherine, Yi, Min, Guadagnolo, B. Ashleigh, May, Caitlin D., Arun, Banu K., Hunt, Kelly K., Lam, Ryan, Lahat, Guy, Hoffman, Aviad, Cormier, Janice N., Feig, Barry W., Lazar, Alexander J., Lev, Dina, Pollock, Raphael E.

“…Background Radiation-associated angiosarcoma (RAAS) is a devastating disease occasionally observed in breast cancer patients treated with radiation. Due to its…”
Get full text

Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma by May, Caitlin D., Landers, Sharon M., Bolshakov, Svetlana, Ma, XiaoYan, Ingram, Davis R., Kivlin, Christine M., Watson, Kelsey L., Sannaa, Ghadah A. Al, Bhalla, Angela D., Wang, Wei-Lien, Lazar, Alexander J., Torres, Keila E.

“…Undifferentiated pleomorphic sarcomas (UPSs) are aggressive mesenchymal malignancies with no definitive cell of origin or specific recurrent genetic hallmarks…”
Get full text

High-resolution analysis of four efficient yeast replication origins reveals new insights into the ORC and putative MCM binding elements by Chang, Fujung, May, Caitlin D, Hoggard, Timothy, Miller, Jeremy, Fox, Catherine A, Weinreich, Michael

“…In budding yeast, the eukaryotic initiator protein ORC (origin recognition complex) binds to a bipartite sequence consisting of an 11 bp ACS element and an…”
Get full text

AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas by May, Caitlin D, Garnett, Jeannine, Ma, XiaoYan, Landers, Sharon M, Ingram, Davis R, Demicco, Elizabeth G, Al Sannaa, Ghadah A, Vu, Tona, Han, Lixia, Zhang, Yi, Kivlin, Christine M, Bolshakov, Svetlana, Kalam, Azad Abul, Liu, Juehui, Zhou, Fuguo, Broccoli, Dominique, Wang, Wei-Lien, Lazar, Alexander J, Pollock, Raphael E, Lev, Dina, Torres, Keila E

“…AXL is a well-characterized, protumorigenic receptor tyrosine kinase that is highly expressed and activated in numerous human carcinomas and sarcomas,…”
Get full text

Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor by Kivlin, Christine M., Watson, Kelsey L., Al Sannaa, Ghadah A., Belousov, Roman, Ingram, Davis R., Huang, Kai-Lieh, May, Caitlin D., Bolshakov, Svetlana, Landers, Sharon M., Kalam, Azad Abul, Slopis, John M., McCutcheon, Ian E., Pollock, Raphael E., Lev, Dina, Lazar, Alexander J., Torres, Keila E.

“…Poly (ADP) ribose polymerase (PARP) inhibitors, first evaluated nearly a decade ago, are primarily used in malignancies with known defects in DNA repair genes,…”
Get full text

Abstract 2458: Targeting checkpoint kinase 1 (CHK1) with the small molecule inhibitor LY2606368 mesylate monohydrate in models of high-risk pediatric cancer yields significant antitumor effects by May, Caitlin D., Beckmann, Richard, Blosser, Wayne, Dowless, Michele, VanWye, Alle, Burke, Teresa, Oakley, Gerard, Stephens, Jennifer, Stewart, Julie, Falcon, Beverly, Stancato, Louis

“…Abstract CHK1 is a serine/threonine protein kinase essential for S-phase and G2/M cell cycle checkpoint regulation following DNA damage. Targeted inhibition of…”
Get full text